Think of Inclisiran as a Niche Med for Lowering LDL

February 2022

Inclisiran (Leqvio) will be the first "small interfering RNA" therapy for lowering cholesterol.

This injectable works at a different step in the same pathway as the PCSK9 inhibitors, alirocumab (Praluent) and evolocumab (Repatha).

Inclisiran prevents formation of the PCSK9 protein...alirocumab and evolocumab prevent PCSK9 binding.

Get concise advice on drug therapy, plus unlimited access to CE

Hospital Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

COVID-19 Know the Latest About COVID-19 MAbs and Remdesivir
COVID-19 Compare COVID-19 Oral Antivirals
COVID-19 Stop VTE Prophylaxis at Discharge for Most COVID-19 Patients
Hypoglycemia Update Hypoglycemia Prevention Strategies
Antiplatelets Individualize Duration of Dual Antiplatelet Therapy in Stent Patients
Pediatrics Promote Appropriate Antibiotic Use for Ear Infections in Kids
GERD Verify Appropriate PPI Use for GERD
HIV & AIDS Promote HIV Pre-Exposure Prophylaxis (PrEP)
Cholesterol Think of Inclisiran as a Niche Med for Lowering LDL
Practice Be Prepared to Dispense Medicinal Leeches